University of Texas Medical Branch at Galveston, Institute for Translational Sciences

UTMB Health

Mission Statement

The Institute for Translational Sciences (ITS) aims to train a new generation of clinical and translational researchers, engage stakeholders and communities in research, address barriers to clinical and translational research, and advance translational research through team-based approaches. The ITS, established in 2007, is the academic home of UTMB’s Clinical Translational Sciences Award (CTSA), funded by the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS). CTSA institutions work together to speed the translation of research discoveries into improved health.

At a Glance


Educational Resources Posted


Consortium News Stories Posted


Events Posted


Opportunities Posted


Publications citing CTSA Program Grant


Users from Hub Registered

UL1 Award

KL2 Award

TL1 Award

Funded Years
2012 - 2021


Serves as a primary source of expertise, training, and education in matters relating to government regulation of externally funded research. Will be responsible and acting on the Associate Director's behalf in their absence. Center for Addiction Research (CAR) Administration : Carry direct responsibility for the operation and oversight of CAR and its administrative team to assure actualization of
The University of Texas Medical Branch at Galveston (UTMB Health) is recruiting a non-tenure track Assistant Professor (Research Ethicist) for membership in the Institute for the Medical Humanities (IMH) and a faculty appointment in the Department of Preventive Medicine and Community Health (PMCH). The IMH is committed to moral inquiry, scholarship, teaching, and professional service in medicine

Poster Sessions

University Of Texas Medical Branch at Galveston

Discovering drugs with the potential to prevent and treat disease takes many years for teams to progress from target validation through initial hits identification, lead optimization, and selection of a candidate for clinical trials. Diseases for which a drug would yield low commercial returns (

University Of Texas Medical Branch at Galveston

CTSA resources are vital to our Hub’s efforts to understand SARS-CoV-2 infection and to prevent and treat COVID-19. In partnership with institutional leadership, our CTSA launched a rapid, multifaceted response protocol to advance the work of Pei-Yong Shi, PhD and his team, who had been working with the Galveston National Laboratory to develop a high throughput assay platform for neutralizing

An Optional Module developed by UTMB's CTSA Hub to support translational research has evolved to meet the needs of stakeholders and now supports investigators across campus in translating thier work to products that can improve health.
University Of Texas Medical Branch at Galveston

Since 2009, we have promoted translational entrepreneurial activities at our CTSA Hub, with an emphasis on engaging scholars and trainees. We are building a culture of innovation and entrepreneurship, as a way to enhance discovery and translation of products that improve health. As an optional function of our second CTSA, we developed the Innovations in Molecular Therapeutics and Devices (IMTD)


Surrogate post-coital testing for contraceptive efficacy against human sperm activity in the ovine vaginal model†

High unintended pregnancy rates are partially due to lack of effective nonhormonal contraceptives; development of safe, effective topical vaginal methods will address this need. Preclinical product safety and efficacy assessment requires in vivo testing in appropriate models. The sheep is a good

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic